NFIL3 Antibody (1218A) [Alexa Fluor® 750] Summary
Recombinant Monoclonal Antibody.
E. coli-derived recombinant mouse NFIL3/E4BP4
Lys140-Arg462
Accession # O08750
Lys140-Arg462
Accession # O08750
Detects NFIL3/E4BP4 in direct ELISAs.
IgG
Monoclonal
Rabbit
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Intracellular Staining by Flow Cytometry 0.25-1 ug/10^6 cells
Packaging, Storage & Formulations
Store the unopened product at 2 – 8 °C. Do not use past expiration date.
Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for NFIL3 Antibody (1218A) [Alexa Fluor® 750]
- E4BP4
- E4BP4IL3BP1
- IL3BP1
- Interleukin-3 promoter transcriptional activator
- Interleukin-3-binding protein 1
- NFIL3
- NF-IL3A
- NFIL3AE4 promoter-binding protein 4
- nuclear factor interleukin 3 regulated protein
- nuclear factor interleukin-3-regulated protein
- nuclear factor, interleukin 3 regulated
- Transcriptional activator NF-IL3A
Background
NFIL3 (Nuclear Factor, Interleukin 3 Regulated), also called E4BP4 (adenovirus E4 promoter binding protein 4), is an approximately 58 kDa transcription factor of the bZIP (basic leucine zipper) family. It is a transcriptional regulator expressed in T and pro-B lymphocytes and cardiomyocytes, binds IL-3 and promoters as a homodimer, and enhances cell survival. NFIL3 has also been shown to be involved in the development of Innate Lymphoid Cells (ILCs; 1,2). The 462 amino acid (aa) human NFIL3 contains a basic DNA binding domain (aa 73-95), a leucine zipper (aa 96-124), and a transcriptional repression domain (aa 299-363) that is potentially regulated by phosphorylation at Ser301 and Ser353. Within the region used as an immunogen, human NFIL3 shares 83% aa sequence identity with mouse and rat NFIL3.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
product targets : ATGL inhibitors